Figure 1:

Outcomes for finerenone versus placebo in FIDELITY-TRH and for spironolactone ± patiromer in AMBER. (A) Office SBP, (B) UACR,^a (C) and hyperkalemia outcomes for finerenone versus placebo in the FIDELITY-TRH subgroup (TRH with moderate–advanced CKD population) at ∼17 weeks (120 days) and for spironolactone ± patiromer in AMBER at 12 weeks (serum [K⁺] >5.5 mmol/L). BL, baseline. ^aIn AMBER, the between-group difference for UACR corresponds to the difference between groups [(spironolactone + patiromer) – (spironolactone + placebo)].